429 related articles for article (PubMed ID: 16515478)
1. Estrogen receptors as therapeutic targets in breast cancer.
Ariazi EA; Ariazi JL; Cordera F; Jordan VC
Curr Top Med Chem; 2006; 6(3):181-202. PubMed ID: 16515478
[TBL] [Abstract][Full Text] [Related]
2. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ; Johnston SR; Howell A
Best Pract Res Clin Endocrinol Metab; 2004 Mar; 18(1):47-66. PubMed ID: 14687597
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
[TBL] [Abstract][Full Text] [Related]
4. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
5. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
Johnston SR
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
7. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
8. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
Musa MA; Khan MO; Cooperwood JS
Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor modulators: an update on recent clinical findings.
Shelly W; Draper MW; Krishnan V; Wong M; Jaffe RB
Obstet Gynecol Surv; 2008 Mar; 63(3):163-81. PubMed ID: 18279543
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
Pickar JH; Komm BS
Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
[TBL] [Abstract][Full Text] [Related]
11. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium.
Labrie F; Labrie C; Bélanger A; Simard J; Giguère V; Tremblay A; Tremblay G
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):213-25. PubMed ID: 11850228
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators in clinical practice: a safety overview.
Ellis AJ; Hendrick VM; Williams R; Komm BS
Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229
[TBL] [Abstract][Full Text] [Related]
13. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
Pinkerton JV; Goldstein SR
Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
[TBL] [Abstract][Full Text] [Related]
14. Future use of selective estrogen receptor modulators and aromatase inhibitors.
Howell A
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4402s-4410s; discussion 4411s-4412s. PubMed ID: 11916232
[TBL] [Abstract][Full Text] [Related]
15. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF
Cancer Treat Rev; 2004 Dec; 30(8):695-706. PubMed ID: 15541579
[TBL] [Abstract][Full Text] [Related]
16. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
Jordan VC; Brodie AM
Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
[TBL] [Abstract][Full Text] [Related]
17. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
18. Use of SERMs for treatment in postmenopausal women.
Pinkerton JV; Thomas S
J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting in the estrogen receptor hormonal pathway.
Katzenellenbogen BS; Frasor J
Semin Oncol; 2004 Feb; 31(1 Suppl 3):28-38. PubMed ID: 15052541
[TBL] [Abstract][Full Text] [Related]
20. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
Maeda T; Ke HZ; Simmons H; Thompson D
Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
